The role of microRNAs in breast cancer stem cells

Abstract

MAO Chang-Fei, WU Jian-Zhong, TANG Jin-Hai. The role of microRNAs in breast cancer stem cells[J]. Journal of International Oncology, 2014, 41(12): 884-887.

［1］ Wicha MS, Liu S, Dontu G. Cancer stem cells: an old ideaa paradigm shift［J］. Cancer Res, 2006, 66(4): 18831890. ［2］ NanaSinkam SP, Croce CM. Clinical applications for micrornas in cancer［J］. Clin Pharmacol Ther, 2013, 93(1): 98104. ［3］ Sempere LF, Christensen M, Silahtaroglu A, et al. Altered microrna expression confined to specific epithelial cell subpopulations in breast cancer［J］. Cancer Res, 2007, 67(24): 1161211620. ［4］ Yu F, Yao H, Zhu P, et al. Let7 regulates self renewal and tumorigenicity of breast cancer cells［J］. Cell, 2007, 131(6): 11091123. ［5］ Johnson CD, EsquelaKerscher A, Stefani G, et al. The let7 microrna represses cell proliferation pathways in human cells［J］. Cancer Res, 2007, 67(16): 77137722. ［6］ Wang Y, Hu X, Greshock J, et al. Genomic DNA copynumber alterations of the let7 family in human cancers［J］. PLoS One, 2012, 7(9): e44399. ［7］ Ambros V. Micrornas: Tiny regulators with great potential［J］. Cell, 2001, 107(7): 823826. ［8］ Yu F, Deng H, Yao H, et al. Mir30 reduction maintains selfrenewal and inhibits apoptosis in breast tumorinitiating cells［J］. Oncogene, 2010, 29(29): 41944204. ［9］ Shimono Y, Zabala M, Cho RW, et al. Downregulation of mirna200c links breast cancer stem cells with normal stem cells［J］. Cell, 2009, 138(3): 592603. ［10］ Iliopoulos D, LindahlAllen M, Polytarchou C, et al. Loss of mir200 inhibition of suz12 leads to polycombmediated repression required for the formation and maintenance of cancer stem cells［J］. Mol cell, 2010, 39(5): 761772. ［11］ Okuda H, Xing F, Pandey PR, et al. miR7 suppresses brain metastasis of breast cancer stemlike cells by modulating klf4［J］. Cancer Res, 2013, 73(4): 14341444. ［12］ Zhu Y, Yu F, Jiao Y, et al. Reduced miR128 in breast tumorinitiating cells induces chemotherapeutic resistance via Bmi1 and ABCC5［J］. Clin Cancer Res, 2011, 17(22): 71057115. ［13］ Qian P, Banerjee A, Wu ZS, et al. Loss of snail regulated mir1282 on chromosome 3p22.3 targets multiple stem cell factors to promote transformation of mammary epithelial cells［J］. Cancer Res, 2012, 72(22): 60366050. ［14］ Yu F, Jiao Y, Zhu Y, et al. Microrna 34c gene downregulation via DNA methylation promotes selfrenewal and epithelialmesenchymal transition in breast tumorinitiating cells［J］. J Biol Chem, 2012, 287(1): 465473. ［15］ Zhang X, Wan G, Mlotshwa S, et al. Oncogenic wip1 phosphatase is inhibited by mir16 in the DNA damage signaling pathway［J］. Cancer Res, 2010, 70(18): 71767186. ［16］ HwangVerslues WW, Chang PH, Wei PC, et al. Mir495 is upregulated by e12/e47 in breast cancer stem cells, and promotes oncogenesis and hypoxia resistance via downregulation of ecadherin and redd1［J］. Oncogene, 2011, 30(21): 24632474. ［17］ Zhang Y, Eades G, Yao Y, et al. Estrogen receptor alpha signaling regulates breast tumorinitiating cells by downregulating mir140 which targets the transcription factor SOX2［J］. J Biol Chem, 2012, 287(49): 4151441522. ［18］ Li Q, Yao Y, Eades G, et al. Downregulation of mir140 promotes cancer stem cell formation in basallike early stage breast cancer［J］. Oncogene, 2014, 33(20): 25892600.

[1]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234.
[3]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238.
[4]	Gong Yan, Chen Honglei.Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer[J]. Journal of International Oncology, 2024, 51(3): 186-190.
[5]	Chen Boguang, Wang Sugui, Zhang Yongjie.Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer[J]. Journal of International Oncology, 2024, 51(2): 73-82.
[6]	Gu Huayan, Zhu Teng, Guo Guilong.Breast microbiota and breast cancer： present and future[J]. Journal of International Oncology, 2024, 51(1): 55-58.
[7]	Wang Jing, Xu Wenting.Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm[J]. Journal of International Oncology, 2023, 50(9): 520-526.
[8]	Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying.Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients[J]. Journal of International Oncology, 2023, 50(9): 527-531.
[9]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng.Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway[J]. Journal of International Oncology, 2023, 50(8): 449-456.
[10]	Pan Shulan, Liu Chang, He Ping.Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer[J]. Journal of International Oncology, 2023, 50(8): 457-462.
[11]	Wang Wende, Zeng De.Research progress on the mechanism of endocrine therapy resistance for breast cancer[J]. Journal of International Oncology, 2023, 50(6): 352-356.
[12]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367.
[13]	Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin.lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway[J]. Journal of International Oncology, 2023, 50(4): 202-207.
[14]	Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong.Research progress on targeted therapy of breast cancer with low expression of HER2[J]. Journal of International Oncology, 2023, 50(4): 236-240.
[15]	Zhou Ting, Xu Shaohua, Mei Lin.Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer[J]. Journal of International Oncology, 2023, 50(3): 144-149.

The role of microRNAs in breast cancer stem cells

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments